Skip to main content
Top
Published in: Obesity Surgery 9/2020

01-09-2020 | Obesity | Brief Communication

Successful Use of Intragastric Balloon Therapy as a Bridge to Heart Transplantation

Authors: Neej J. Patel, Victoria Gómez, D. Eric Steidley, Lori Roust, Juan Carlos Leoni Moreno, Neena S. Abraham, Rahul Pannala

Published in: Obesity Surgery | Issue 9/2020

Login to get access

Abstract

Obesity is an important limiting factor for heart transplantation (HT) in patients with congestive heart failure (CHF). Achieving substantial weight loss is challenging in this population due to activity limitations and fluid retention. Endoscopic bariatric therapies (EBTs) including intragastric balloons (IGB) are effective primary weight loss therapies. IGBs have also been successfully utilized as a bridge therapy prior to liver transplantation and, in one case report, prior to HT. Potential advantages of IGBs in this population include low bleeding risk and less invasiveness as compared to other EBTs and surgery. We report the successful use of IGB as a bridge therapy in two patients with class II obesity and end-stage CHF requiring left ventricular assist devices (LVAD), anticoagulation, antiplatelet, and inotrope therapy.
Literature
1.
go back to reference Mehra MR, Canter CE, Hannan MM, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant. 2016;35(1):1–23.CrossRef Mehra MR, Canter CE, Hannan MM, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant. 2016;35(1):1–23.CrossRef
2.
go back to reference Russo MJ, Hong KN, Davies RR, et al. The effect of body mass index on survival following heart transplantation: do outcomes support consensus guidelines? Ann Surg. 2010;251(1):144–52.CrossRef Russo MJ, Hong KN, Davies RR, et al. The effect of body mass index on survival following heart transplantation: do outcomes support consensus guidelines? Ann Surg. 2010;251(1):144–52.CrossRef
3.
go back to reference Turkeltaub JA, Edmundowicz SA. Endoscopic bariatric therapies: Intragastric balloons, tissue apposition, and aspiration therapy. Curr Treat Options Gastroenterol. 2019;17(2):187–201.CrossRef Turkeltaub JA, Edmundowicz SA. Endoscopic bariatric therapies: Intragastric balloons, tissue apposition, and aspiration therapy. Curr Treat Options Gastroenterol. 2019;17(2):187–201.CrossRef
4.
go back to reference Gomez V, Woodman G, Abu Dayyeh BK. Delayed gastric emptying as a proposed mechanism of action during intragastric balloon therapy: results of a prospective study. Obesity. 2016;24(9):1849–53.CrossRef Gomez V, Woodman G, Abu Dayyeh BK. Delayed gastric emptying as a proposed mechanism of action during intragastric balloon therapy: results of a prospective study. Obesity. 2016;24(9):1849–53.CrossRef
5.
go back to reference Abu Dayyeh BK, Kumar N, Edmundowicz SA, et al. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc. 2015;82:425–38.e5.CrossRef Abu Dayyeh BK, Kumar N, Edmundowicz SA, et al. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc. 2015;82:425–38.e5.CrossRef
6.
go back to reference Vargas EJ, Pesta CM, Bali A, et al. Single fluid-filled intragastric balloon safe and effective for inducing weight loss in a real-world population. Clin Gastroenterol Hepatol. 2016;16(7):1073–1080.e1.CrossRef Vargas EJ, Pesta CM, Bali A, et al. Single fluid-filled intragastric balloon safe and effective for inducing weight loss in a real-world population. Clin Gastroenterol Hepatol. 2016;16(7):1073–1080.e1.CrossRef
7.
go back to reference Storm AC, Lakdawala NK, Thompson CC. Intragastric balloon for management of morbid obesity in a candidate for heart transplantation. J Heart Lung Transplant. 2017 July;36(7):820–1.CrossRef Storm AC, Lakdawala NK, Thompson CC. Intragastric balloon for management of morbid obesity in a candidate for heart transplantation. J Heart Lung Transplant. 2017 July;36(7):820–1.CrossRef
8.
go back to reference Sullivan S, Kumar N, Edmundowicz SA, et al. ASGE position statement on endoscopic bariatric therapies in clinical practice. Gastrointest Endosc. 2015;82:767–72.CrossRef Sullivan S, Kumar N, Edmundowicz SA, et al. ASGE position statement on endoscopic bariatric therapies in clinical practice. Gastrointest Endosc. 2015;82:767–72.CrossRef
9.
go back to reference Choudhary NS, Puri R, Saraf N, et al. Intragastric balloon as a novel modality for weight loss in patients with cirrhosis and morbid obesity awaiting liver transplantation. Indian J Gastroenterol. 2016;35(2):113–6.CrossRef Choudhary NS, Puri R, Saraf N, et al. Intragastric balloon as a novel modality for weight loss in patients with cirrhosis and morbid obesity awaiting liver transplantation. Indian J Gastroenterol. 2016;35(2):113–6.CrossRef
Metadata
Title
Successful Use of Intragastric Balloon Therapy as a Bridge to Heart Transplantation
Authors
Neej J. Patel
Victoria Gómez
D. Eric Steidley
Lori Roust
Juan Carlos Leoni Moreno
Neena S. Abraham
Rahul Pannala
Publication date
01-09-2020
Publisher
Springer US
Published in
Obesity Surgery / Issue 9/2020
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-020-04572-7

Other articles of this Issue 9/2020

Obesity Surgery 9/2020 Go to the issue